Australia's LTR Pharma gains on US deal for Roxus

Ltr Pharma

11/06/2026 05:20

** Shares of Australia's LTR Pharma LTP.AX rise as much as 25.9% to A$0.535, their biggest gain since June 5
** The clinical-stage biopharma firm executed a binding term sheet with U.S.-based pharmacy operator Strive Specialities
** The binding term sheet establishes exclusive U.S. pharmacy fulfillment rights for ROXUS, an intranasal treatment for erectile dysfunction
** Around 2.1 mln shares change hands, nearly 4x 30-day average
** LTP down 31.3% YTD

 (Reporting by Keshav Singh Chundawat in Bengaluru)
 ((Keshav.singhchundawat@thomsonreuters.com))